Randomized Double-Blind Trial in Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen for 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen.

Trial Profile

Randomized Double-Blind Trial in Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen for 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2016

At a glance

  • Drugs Exemestane (Primary) ; Tamoxifen
  • Indications Breast cancer; Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms IES; PathIES
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Feb 2012 Planned patient number of the sub study (UKCRN 4208) is 2740.
    • 24 Feb 2012 Planned end date of the sub study (UKCRN 4208) is 25 Feb 2003.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top